These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22740874)

  • 1. Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer.
    Rhodes LV; Tilghman SL; Boue SM; Wang S; Khalili H; Muir SE; Bratton MR; Zhang Q; Wang G; Burow ME; Collins-Burow BM
    Oncol Lett; 2012 Jan; 3(1):163-171. PubMed ID: 22740874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glyceollins trigger anti-proliferative effects through estradiol-dependent and independent pathways in breast cancer cells.
    Lecomte S; Chalmel F; Ferriere F; Percevault F; Plu N; Saligaut C; Surel C; Lelong M; Efstathiou T; Pakdel F
    Cell Commun Signal; 2017 Jun; 15(1):26. PubMed ID: 28666461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Glyceollins as Novel Aryl Hydrocarbon Receptor Ligands and Their Role in Cell Migration.
    Pham TH; Lecomte S; Le Guevel R; Lardenois A; Evrard B; Chalmel F; Ferriere F; Balaguer P; Efstathiou T; Pakdel F
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis.
    Salvo VA; Boué SM; Fonseca JP; Elliott S; Corbitt C; Collins-Burow BM; Curiel TJ; Srivastav SK; Shih BY; Carter-Wientjes C; Wood CE; Erhardt PW; Beckman BS; McLachlan JA; Cleveland TE; Burow ME
    Clin Cancer Res; 2006 Dec; 12(23):7159-64. PubMed ID: 17145841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis.
    Xu W; Song C; Wang X; Li Y; Bai X; Liang X; Wu J; Liu J
    Aging (Albany NY); 2021 Jan; 13(1):228-240. PubMed ID: 33472170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study.
    Chang LC; Hsieh MT; Yang JS; Lu CC; Tsai FJ; Tsao JW; Chiu YJ; Kuo SC; Lee KH
    Int J Oncol; 2018 Jan; 52(1):67-76. PubMed ID: 29138806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.
    Gründker C; Föst C; Fister S; Nolte N; Günthert AR; Emons G
    Breast Cancer Res; 2010; 12(4):R49. PubMed ID: 20630060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptor (TLR) gene expression and immunostimulatory effect of CpG oligonucleotides in hormone receptor positive cell line T47D and triple negative breast cancer cell line MDA-MB-468.
    Natarajan S; Ranganathan M
    Immunopharmacol Immunotoxicol; 2020 Oct; 42(5):408-415. PubMed ID: 32686546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.
    Rhodes LV; Bratton MR; Zhu Y; Tilghman SL; Muir SE; Salvo VA; Tate CR; Elliott S; Nephew KP; Collins-Burow BM; Burow ME
    Exp Cell Res; 2011 Nov; 317(18):2573-81. PubMed ID: 21906588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of miRNA-135b on proliferation, invasion and migration of triple-negative breast cancer by targeting APC].
    Xin H; Jiang D; Lü Z; Sun S; Kong J; Li F
    Zhonghua Yi Xue Za Zhi; 2015 Aug; 95(30):2474-7. PubMed ID: 26711213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.
    Li G; Yang M; Zuo L; Wang MX
    Oncol Lett; 2018 Jun; 15(6):9934-9940. PubMed ID: 29805690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogenic activity of glyceollins isolated from soybean elicited with Aspergillus sojae.
    Kim HJ; Suh HJ; Kim JH; Kang SC; Park S; Lee CH; Kim JS
    J Med Food; 2010 Apr; 13(2):382-90. PubMed ID: 20192844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
    Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
    J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
    Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
    Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
    BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted inhibition of Notch1 gene enhances the killing effects of paclitaxel on triple negative breast cancer cells.
    Zhou YF; Sun Q; Zhang YJ; Wang GM; He B; Qi T; Zhou Y; Li XW; Li S; He L
    Asian Pac J Trop Med; 2017 Feb; 10(2):179-183. PubMed ID: 28237486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.